Manoj K: How Incyte Could Help Transform Care for Patients With von Willebrand Disease
Manoj K, Senior Partner and Life Sciences Industry Leader at IBM Consulting, shared a post on LinkedIn:
“Twice a week. Every week. For life. That has been the burden for patients with von Willebrand disease (VWD), the most common inherited bleeding disorder more prevalent than hemophilia A and B combined.
While hemophilia advanced with gene therapies and extended factors, VWD patients relied on frequent IV plasma-derived concentrates, unchanged since the 1980s. That changed with today’s news.
Incyte is nearing a deal to acquire Star Therapeutics for up to $2B ($1.25B upfront plus $750M milestones). The prize: VGA039, a first-in-class once-monthly subcutaneous monoclonal antibody self-administered at home, no IV, no hospital.
At the center of the deal is VGA039 Star’s first-in-class monoclonal antibody targeting Protein S, currently in pivotal Phase 3 trials for von Willebrand disease.
The therapy, known as VGA039, is in late-stage clinical testing and has received Fast Track designation from the U.S. FDA. For Incyte, this is the hematology anchor their post-Jakafi pipeline has been missing.
The human stakes are straightforward. Today’s VWD patients endure two to three IV infusions every week hospital-dependent, schedule-disrupting, relentless.
VGA039 replaces that entirely with a once-monthly subcutaneous injection, self-administered at home. Same protection. A fraction of the burden.
The acquisition would also mark the first major deal under Incyte CEO Bill Meury, who took over last year and has emphasized acquisitions as a way to offset future revenue pressure from the expected 2028 patent expiration of the company’s top-selling blood cancer drug, Jakafi.
Star Therapeutics backed by Sofinnova Partners, RA Capital Management, and Catalio Capital Management had explored an IPO before the math of a strategic sale proved more compelling.
Incyte‘s expertise in blood disorders could help position the company to commercialize VGA039 if it wins regulatory approval.”
Stay updated with Hemostasis Today.
-
Jun 8, 2026, 03:05Shamsunisha Yusuff: Iron Down, Platelets Up in a Young CBC ?
-
Jun 8, 2026, 03:03Samwel Mikaye: D-Dimer – A Marker of Blood Clot Breakdown
-
Jun 8, 2026, 02:59Vinita Madhuri: Our Engagement, A Lifeline for Thalassemia Patients
-
Jun 7, 2026, 22:11Lucia Härtel: Exercise, IL-10 Signaling, and Post-Stroke Brain Plasticity
-
Jun 7, 2026, 19:35Ashish Pemawat: Is the 4.5-Hour Thrombolysis Window Becoming Less Relevant?
-
Jun 7, 2026, 18:25Nita Radhakrishnan: Every Child Cured Is a Reminder of What Can Be Achieved When We Work Together
-
Jun 7, 2026, 18:24Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
-
Jun 7, 2026, 18:21Gulab Makwana: Complete Guide to Clotting Factors – Understanding the Coagulation System
-
Jun 7, 2026, 18:15Chuhan Dong: Presenting My Research on Antibody-Mediated RBC Clearance at Canadian Blood Services